BCA
VRNA

Burren Capital Advisors’s Verona Pharma VRNA Stock Holding History

Burren Capital Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$6.74M Buy
+63,198
New +$6.6M 20.43% 1

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Burren Capital Advisors's VRNA Position: Q3 2025 in Review

Burren Capital Advisors opened a new position in Verona Pharma (VRNA) in Q3 2025: 63,198 shares worth $6.74M. The stake represents 20.43% of the portfolio and ranks #1 among its holdings.

243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Burren Capital Advisors held 63,198 shares of Verona Pharma worth $6.74M as of Q3 2025.
  • Verona Pharma was a new Burren Capital Advisors position in Q3 2025.
  • Verona Pharma made up 20.43% of Burren Capital Advisors's portfolio in Q3 2025, its #1 holding.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Burren Capital Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.